NICE is one of the most advanced cost effectiveness assessment bodies operating in the major pharmaceutical markets. Since it was established it has had an increasing impact on the availability of new drugs in England and Wales, but has also generated considerable attention globally.
Scope
Overview of the UK pricing and reimbursement system and the role NICE plays in it
Analysis of the key issues facing NICE and the measures being taken to rectify them
Discussion of case studies to illustrate the effect of and response to key NICE rulings
Highlights
NICE plays a key role in the UK healthcare system although it does not currently assess all new drug approvals. Its impact is also felt outside the UK as organizations and indeed individual physicians in other countries also monitor its conclusions. A variety of stakeholders have input into the NICE topic selection process including patients, physicians and the pharmaceutical industry. To date cancer drugs have accounted for the largest number of completed assessments.
Reasons to Purchase
Understand how NICE assessments impact the pricing and reimbursement environment in England and Wales
Gain insight into the key issues with NICE assessments and the changes which are being used to tackle them
Benchmark the impact and response to the outcome of key NICE assessments
